会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Crystalline micropowder particles
    • 结晶微粉颗粒
    • US08198446B2
    • 2012-06-12
    • US12601150
    • 2008-05-20
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • C07D489/08
    • A61K9/1688A61K9/2018A61K31/485C07D489/08
    • Crystalline particles of N-(17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 μm, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 μm, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.
    • 公开了N-(17-环丙基甲基-4,5α-环氧-3,14-二羟基 - 吗啡喃-6'-基) - 邻苯二甲酰亚胺或其药学上可接受的盐的结晶颗粒。 结晶粒子具有粒径分布,其中由具有小直径的颗粒累积计算的体积分布的累积频率达到50%的点处的粒径(D50)在1至30μm的范围内,并且粒径 (D90)在由具有较小直径的颗粒累积计算的体积分布的累积频率达到90%的点处不超过90μm,该结晶颗粒的结晶度不小于80%。 通过结晶颗粒,可以提高活性物质的生物利用度,同时确保化合物的储存稳定性。
    • 8. 发明申请
    • CRYSTALLINE MICROPOWDER PARTICLES
    • 晶体微波颗粒
    • US20100160634A1
    • 2010-06-24
    • US12601150
    • 2008-05-20
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • Masahiro AkimotoToshikazu KomagataMotohiro ShirakiAkihiro Ando
    • C07D489/08
    • A61K9/1688A61K9/2018A61K31/485C07D489/08
    • Crystalline particles of N-(17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 μm, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 μm, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.
    • 公开了N-(17-环丙基甲基-4,5α-环氧-3,14-二羟基 - 吗啡喃-6'-基) - 邻苯二甲酰亚胺或其药学上可接受的盐的结晶颗粒。 结晶粒子具有粒径分布,其中由具有小直径的颗粒累积计算的体积分布的累积频率达到50%的点处的粒径(D50)在1至30μm的范围内,并且粒径 (D90)在由具有较小直径的颗粒累积计算的体积分布的累积频率达到90%的点处不超过90μm,该结晶颗粒的结晶度不小于80%。 通过结晶颗粒,可以提高活性物质的生物利用度,同时确保化合物的储存稳定性。